secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXAGEN INC. (XGN)
CIK:        0001274737
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001274737-25-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exagen gets conditional NY approval for new SLE/RA biomarkers; reports record 2024 revenue of $55.3-55.8M
--------------------------------------------------------------------------------

- Conditional NY State approval for new SLE and RA biomarker assays on AVISE CTD; commercial launch January 2025.
- Preliminary FY2024 revenue $55.3-$55.8M (record), net loss $14.8-$15.8M, adjusted EBITDA ($9.8)-($10.8M).
- AVISE CTD trailing 12-mo ASP $408-$412, up $72-$76 vs Q4 2023; net neutral cash usage in Q4.
- Cash, cash equivalents and restricted cash $22.2M as of Dec 31, 2024.
- CEO says profitability 'firmly within reach' with strong growth catalysts entering 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1274737/000127473725000003/0001274737-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1274737/000127473725000003/exdx-20250112.htm
  HTML page:      https://secwatch.observer/filing/0001274737-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer